ABSCINT specializes in advanced in vivo imaging diagnostics, focusing on developing innovative PET tracers using single-domain antibodies (sdAbs) for precision targeting. ABSCINT’s primary product is a specific anti-HER2 PET tracer, which enables comprehensive whole-body imaging for evaluating disease heterogeneity in HER2-low and HER2-positive breast cancer. This non-invasive technology offers rapid imaging results within 90 minutes, with minimal radiation exposure. This innovation also opens the door to HER2 reclassification via image-guided biopsies, enhancing diagnostic accuracy, patient care, and monitoring of treatment efficacy. -- ABSCINT, Harnessing Antibody Scintigraphy for Precision Diagnostics in Breast Cancer and Beyond --
| Website | https://abscint.com |
| Employees | 8 (3 on RocketReach) |
| Founded | 2020 |
| Industry | Biotechnology Research |
| Keywords | Pet Imaging, Cancer Diagnostics, In Vivo Imaging, Oncology Imaging, Precision Medicine, Targeted Therapy, Molecular Imaging, Diagnostic Imaging, Radiopharmaceutical, Drug Development, Biopharmaceutical, Antibody Engineering, Pharmaceutical Research, Medical Imaging, Advanced Imaging |
| Competitors | Thermo Fisher Scientific, Biosynth, Eppendorf Group, Sartorius, Agilent Technologies, Merck Group, Waters Corporation, MilliporeSigma, PerkinElmer, Inc., Bio-Rad Laboratories +45 more (view full list) |
Looking for a particular ABSCINT employee's phone or email?
ABSCINT Questions
Karine Clauwaert is the CEO of ABSCINT.
3 people are employed at ABSCINT.
Top ABSCINT Employees
Related Companies
